Living Cell Technologies Ltd. (AU:1AI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Algorae Pharmaceuticals has announced promising preclinical results for its drug candidate AI-168, which showed significant cardioprotective effects, surpassing traditional beta blockers. The company is seeking patent protection for AI-168 after these successful studies, positioning the drug to potentially capture a share of the lucrative cardiovascular treatment market.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.